Bone health management in patients with prostate cancer

Authored by Alison Birtle, published on 2026-05-04 18:00:10.0

The algorithm is broadly aligned with contemporary guidance that men receiving ADT are at increased risk of bone loss and fracture and should undergo baseline fracture risk assessment with BMD (DEXA) where feasible, lifestyle/calcium/vitamin D optimization, and pharmacologic therapy for higher-risk patients. Use of antiresorptives (bisphosphonates or denosumab) is consistent with major osteoporosis/oncology guidance, and denosumab has direct RCT evidence for fracture reduction in men on ADT. Some regimen specifics (e.g., zoledronic acid dosing frequency with radium-223, thresholds such as ≥4%/year BMD loss, and fixed treatment durations/stop rules) are more institution- or osteoporosis-practice–derived and not uniformly standardized across major prostate-cancer guidelines.FEBRUARY 2026 Clinical Oncology National guideline of bone health management in patients with prostate cancer.

  1. Androgen Deprivation Theory (ADT) duration and fracture risk group
    • 0–6 months ADT (Green group: population/low risk) ADVISE
      • No pharmacological intervention
        Unless opportunistic risk factor assessment highlights increased risk. To be managed by GP
    • ≥ 6 months ADT (Amber group: moderate risk) ASSESS
      • Monitor Or Treat as per RED group
        • Baseline DEXA (if available) or using clinical judgement in presence of following risk factors
          • Risk factors
            Consider bone protection treatment if ≥ 2 of the following. Increased risk of fracture is defined as: Age >70 years If <70 years with a BMD T score at the lumbar spine, total hip or femoral neck < −1.0 A history of an osteoporotic fracture Oral prednisolone ≥7.5 mg/day or equivalent
            • Continue monitoring/repeat with DEXA 1–3 yearly
              Dependent on risk factors above and ongoing rate of bone loss between scans. Treat if ≥4% per year
              • Treatment options
                • Parenteral option (eg patient/clinician preference, oral agents intolerance, or radium 223 / fracture / or SRE on oral treatment):
                  A. Zoledronic acid 5 mg IV yearly for 3 years (or 4–12 weekly if starting on radium-223 at the same time as newly starting BPAs; consider stopping after 3 years if no SREs or extend to 5 years if had an SRE during this period) If not tolerated: B. Denosumab SC 60 mg every 6 months for 3 years for patients at increased risk of fracture (see notes below) or 120 mg every 4 weeks
                  • Follow up (any prostate clinic):
                    Re-assess fracture risk if re-fracture occurs or risk factors changed
                    • *End of prostate cancer treatment
                      Re-assess fracture risk and consider stopping bone protection treatment after 5 years (can continue longer if new fracture occurs)
                • Oral option:
                  Weekly PO alendronic acid 70mg or risedronate sodium 35 mg for 5 years
                  • Follow up (any prostate or GP clinic):
                    Assess tolerance after 3 months, and adherence after 1 year (reassess fracture risk if new fracture occurs or risk factors changed)
                    • End of prostate cancer treatment
                      Re-assess fracture risk and consider stopping bone protection treatment after 5 years
                  • Or if intolerant
                    • Parenteral option (eg patient/clinician preference, oral agents intolerance, or radium 223 / fracture / or SRE on oral treatment):
                      A. Zoledronic acid 5 mg IV yearly for 3 years (or 4–12 weekly if starting on radium-223 at the same time as newly starting BPAs; consider stopping after 3 years if no SREs or extend to 5 years if had an SRE during this period) If not tolerated: B. Denosumab SC 60 mg every 6 months for 3 years for patients at increased risk of fracture (see notes below) or 120 mg every 4 weeks
                      • Follow up (any prostate clinic):
                        Re-assess fracture risk if re-fracture occurs or risk factors changed
                        • *End of prostate cancer treatment
                          Re-assess fracture risk and consider stopping bone protection treatment after 5 years (can continue longer if new fracture occurs)
    • Lifelong hormones ± additional therapies (Red group: high risk) TREAT
      • Start bone protection agents (BPAs)
        • Bisphosphonate / denosumab and calcium / vitamin D supplement
          Vitamin D level should be measured and deficiency (<25 nmol/L) corrected with loading regimen if patient is symptomatic (eg bone pain, lower back pain, muscle pain or weakness) or before starting IV zoledronic acid or SC denosumab. Vitamin D level is not routinely required in asymptomatic patients starting oral bisphosphonates. Consider use concomitantly if receiving radium-223 and step down to oral or continuous after completing radium-223 depending on patient fitness, preference and logistics on shared decision-making.
          • Treatment options
            • Parenteral option (eg patient/clinician preference, oral agents intolerance, or radium 223 / fracture / or SRE on oral treatment):
              A. Zoledronic acid 5 mg IV yearly for 3 years (or 4–12 weekly if starting on radium-223 at the same time as newly starting BPAs; consider stopping after 3 years if no SREs or extend to 5 years if had an SRE during this period) If not tolerated: B. Denosumab SC 60 mg every 6 months for 3 years for patients at increased risk of fracture (see notes below) or 120 mg every 4 weeks
              • Follow up (any prostate clinic):
                Re-assess fracture risk if re-fracture occurs or risk factors changed
                • *End of prostate cancer treatment
                  Re-assess fracture risk and consider stopping bone protection treatment after 5 years (can continue longer if new fracture occurs)
            • Oral option:
              Weekly PO alendronic acid 70mg or risedronate sodium 35 mg for 5 years
              • Follow up (any prostate or GP clinic):
                Assess tolerance after 3 months, and adherence after 1 year (reassess fracture risk if new fracture occurs or risk factors changed)
                • End of prostate cancer treatment
                  Re-assess fracture risk and consider stopping bone protection treatment after 5 years
              • Or if intolerant
                • Parenteral option (eg patient/clinician preference, oral agents intolerance, or radium 223 / fracture / or SRE on oral treatment):
                  A. Zoledronic acid 5 mg IV yearly for 3 years (or 4–12 weekly if starting on radium-223 at the same time as newly starting BPAs; consider stopping after 3 years if no SREs or extend to 5 years if had an SRE during this period) If not tolerated: B. Denosumab SC 60 mg every 6 months for 3 years for patients at increased risk of fracture (see notes below) or 120 mg every 4 weeks
                  • Follow up (any prostate clinic):
                    Re-assess fracture risk if re-fracture occurs or risk factors changed
                    • *End of prostate cancer treatment
                      Re-assess fracture risk and consider stopping bone protection treatment after 5 years (can continue longer if new fracture occurs)
tosprivacy